RGC Resources Inc. (RGCO) Reaches $26.78 52-Week High; TAXUS CARDIUM PHARMA (CRXM) SI Increased By 31.58%

June 5, 2017 - By Adrian Erickson

TAXUS CARDIUM PHARMA (OTCMKTS:CRXM) had an increase of 31.58% in short interest. CRXM’s SI was 10,000 shares in June as released by FINRA. Its up 31.58% from 7,600 shares previously. With 14,400 avg volume, 1 days are for TAXUS CARDIUM PHARMA (OTCMKTS:CRXM)’s short sellers to cover CRXM’s short positions. About 1,000 shares traded. Taxus Cardium Pharmaceuticals Group Inc (OTCMKTS:CRXM) has 0.00% since June 5, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock of RGC Resources Inc. (NASDAQ:RGCO) hit a new 52-week high and has $29.19 target or 9.00% above today’s $26.78 share price. The 9 months bullish chart indicates low risk for the $212.18M company. The 1-year high was reported on Jun, 5 by Barchart.com. If the $29.19 price target is reached, the company will be worth $19.10 million more. About 863 shares traded. RGC Resources Inc. (NASDAQ:RGCO) has risen 62.35% since June 5, 2016 and is uptrending. It has outperformed by 45.65% the S&P500.

Since January 3, 2017, it had 22 insider purchases, and 0 sales for $23,851 activity. On Wednesday, March 1 SMOOT RAYMOND D JR bought $2,333 worth of RGC Resources Inc. (NASDAQ:RGCO) or 125 shares. D ORAZIO JOHN S bought $999 worth of RGC Resources Inc. (NASDAQ:RGCO) on Wednesday, February 1. On Wednesday, February 1 Nester Paul W bought $297 worth of RGC Resources Inc. (NASDAQ:RGCO) or 11 shares. Shares for $895 were bought by AGEE NANCY H on Thursday, June 1.

RGC Resources, Inc. is an energy services company. The company has market cap of $212.18 million. The Firm is engaged in the regulated sale and distribution of natural gas to residential, commercial and industrial clients in Roanoke, Virginia, and the surrounding localities, through its Roanoke Gas Company (Roanoke Gas) subsidiary. It has a 31.05 P/E ratio. Roanoke Gas also provides certain non-regulated services.

Investors sentiment decreased to 1 in 2016 Q4. Its down 0.33, from 1.33 in 2016Q3. It dived, as 1 investors sold RGC Resources Inc. shares while 5 reduced holdings. 1 funds opened positions while 5 raised stakes. 656,229 shares or 2.28% less from 671,535 shares in 2016Q3 were reported. Morgan Stanley reported 22,220 shares stake. Bb&T Securities has 30,200 shares for 0.01% of their portfolio. Commonwealth Equity Svcs has invested 0% in RGC Resources Inc. (NASDAQ:RGCO). Gabelli Funds Ltd Liability Corporation reported 56,000 shares. Pnc Gru stated it has 3,600 shares or 0% of all its holdings. Moreover, Dalton Greiner Hartman Maher & Communication has 0.13% invested in RGC Resources Inc. (NASDAQ:RGCO) for 89,842 shares. 38,925 are owned by North Star Invest Mgmt. Dimensional Fund Advisors Limited Partnership accumulated 0% or 45,727 shares. 80,037 are held by Cutter And Brokerage Inc. Vanguard Group Inc Inc holds 0% or 18,336 shares in its portfolio. Hennessy Inc reported 39,645 shares. Fca Tx has 0.29% invested in RGC Resources Inc. (NASDAQ:RGCO). State Bank Of America Corp De reported 4,400 shares. Blackrock Fund Advisors reported 0% of its portfolio in RGC Resources Inc. (NASDAQ:RGCO). Price T Rowe Associate Md has 0% invested in RGC Resources Inc. (NASDAQ:RGCO) for 8,586 shares.

Analysts await RGC Resources Inc. (NASDAQ:RGCO) to report earnings on August, 7.

Taxus Cardium Pharmaceuticals Group Inc. is engaged in managing a medical technologies portfolio of equity and potential royalty-driven investments. The company has market cap of $2.43 million. The Company’s portfolio includes Angionetics, Inc. ; Activation Therapeutics, Inc. (Activation Therapeutics); LifeAgain Insurance Solutions, Inc. (LifeAgain), and a minority investment in Healthy Brands Collective. It currently has negative earnings. Angionetics is its subsidiary focused on late-stage clinical development and commercialization of Generx, which is an angiogenic gene therapy product candidate designed for medical revascularization for treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.